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Abstract Rationale: Accumulating evidence suggests a
potential role for the 5-HT6 receptor in cognitive function
and the potential use of 5-HT6 receptor antagonists in the
treatment of learning and memory disorders. Objec-
tives: The aim of the current study was to investigate
the effect of the selective 5-HT6 receptor antagonist,
Ro 04-6790, on both the performance of normal adult rats
and restoration of a pharmacological disruption of
memory function produced by the non-selective musca-
rinic receptor antagonist, scopolamine, or the dopamine
D2 receptor antagonist, raclopride, in a rodent model of
recognition memory. Methods: Passive, perceptually
based, recognition memory was assessed using a novel
object discrimination task. Following habituation to an
arena, rats were presented with two identical objects
during trial 1 (T1) and a novel and familiar object during
trial 2 (T2). The time spent exploring the two objects in
each trial was measured and novel object discrimination
assessed in T2. Results: In the absence of drug all rats
spent an equal time exploring the two identical objects in
T1 but more time exploring the novel object in T2.
Scopolamine (but not N-methylscopolamine) and raclo-
pride both produced a dose-dependent reduction in novel
object discrimination whilst the 5-HT6 receptor antago-
nist, Ro 04-6790, had no effect on discrimination when
given alone but completely reversed the scopolamine- but
not the raclopride-induced deficit. Conclusion: This study
demonstrates that acute administration of Ro 04-6790
reverses a cholinergic but not a dopaminergic deficit in a
rodent model of recognition memory and provides further
support for a role of the 5-HT6 receptor in the regulation
of cognitive function.
Keywords Memory · Rats · Ro 04-6790 · 5-HT6 receptor
antagonists
Introduction
The 5-HT6 receptor is one of the most recent additions to
the fifteen mammalian 5-HT receptors identified to date
(Hoyer et al. 2002). Following the discovery of the rodent
5-HT6 receptor using molecular biology (Monsma et al.
1993: Ruat et al. 1993), identification of the human
analogue quickly followed (Kohen et al. 1996). These two
receptor proteins comprise a linear chain of 438 (rat) and
440 (human) amino acids with a typical seven transmem-
brane spanning G-protein linked structure, are positively
coupled to adenylyl cyclase and are 89% homologous.
Research into the functional role of the receptor was
initially hampered due to a lack of selective ligands and
early studies made use of antisense oligonucleotides to
reduce 5-HT6 receptor expression (Bourson et al. 1995;
Bentley et al. 1997; Yoshioka et al. 1998; Hamon et al.
1999; Otano et al. 1999). However, recently a number of
selective 5-HT6 receptor antagonists have been charac-
terized (Sleight et al. 1998; Bromidge et al. 1999; Issac et
al. 2000; Lee et al. 2000; Tsai et al. 2000; Slassi et al.
2000; Bs et al. 2001; Russell et al. 2001), providing
more selective tools with which to probe the functional
role of this receptor. To date, the receptor has been
implicated in psychotic disorders (Monsma et al. 1993;
Roth et al. 1994; Tsai et al. 1999; Yu et al. 1999; Pouzet
et al. 2002), affective disorders (Roth et al. 1994; Yau et
al. 1997; Vogt et al. 2000), anxiety (Yoshioka et al. 1998;
Hamon et al. 1999; Otano et al. 1999), epilepsy (Rout-
ledge et al. 2000) and potentially the regulation of food
consumption (Bentley et al. 1997, 1999b; Woolley et al.
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2001), but the most compelling evidence suggests a role
for the receptor in cognitive function.
Both chronic i.c.v. injection of a 5-HT6 receptor
specific antisense oligonucleotide (A.O.; Bourson et al.
1995) and acute systemic administration of 4-amino-N-
(2,6) bis-methyl-amino-pyrimidin-4-yl-benzene sulpho-
namide (Ro 04-6790, Bentley et al. 1999a) produced a
specific behavioural syndrome of stretching, which was
blocked by atropine but not by haloperidol, suggesting
that the 5-HT6 receptor may regulate central cholinergic,
but not dopaminergic, neurotransmission. Consistent with
this proposal, Ro 04-6790 blocked scopolamine-induced
ipsilateral rotations but had no effect on apopmorphine-
induced contralateral rotations in 6-hydroxydopamine (6-
OHDA) lesioned rats (Bourson et al. 1998). More
recently, microdialysis studies have demonstrated elevat-
ed levels of acetylcholine in the hippocampus and frontal
cortex of the conscious rat following treatment with either
Ro 04-6790 (Shiraz-Southall et al. 2002) or the structural
analogue Ro 65-7199 (Sleight et al. 1999). Given the well
documented cholinergic link to memory function (Bartus
et al. 1982), a 5-HT6 receptor-cholinergic interaction
could account for the modulation of cognition seen with
5-HT6 receptor antagonists.
We previously demonstrated enhanced retention (but
not acquisition) of a learnt platform position in normal
adult rats following chronic treatment with a specific 5-
HT6 receptor-directed A.O. and the selective 5-HT6
receptor antagonist, Ro 04-6790, after acquisition training
in the Morris water maze (Bentley et al. 1997; Woolley et
al. 2001). This was also seen with other 5-HT6 receptor
antagonists (5-chloro-N-(4-methoxy-3-piperazin-1-yl-phe-
nyl)-3-methyl-2-benzothio-phene sulphonamide (SB-
271046) and N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-
3-piperazin-1-yl benzene sulphonamide (SB-357134; Rog-
ers et al. 1999; Rogers and Hagan 2001), suggesting that
the 5-HT6 receptor may regulate long-term memory in
normal adult rats. More recently, Stean et al. (2002)
demonstrated enhanced acquisition as measured by path
length, in addition to enhanced retention of a learnt
platform position in the Morris water maze following
chronic administration of SB-357134 (10 mg/kg PO, twice
daily, 7 days prior to training), implying a role for the 5-
HT6 receptor in both the learning and mnemonic processes
involved in this spatial learning task. However, only few
preliminary investigations have examined the effect of 5-
HT6 receptor antagonists on rodent models of impaired
memory function, in order to determine their potential
utility as therapeutic agents for the treatment of Alzhei-
mer’s disease (Rogers et al. 1999, 2000; Menses 2001).
Assessing passive perceptually based recognition
memory, the novel object discrimination task takes
advantage of the spontaneous preference of rodents for
novelty and does not require reinforcement of behaviour
by food reward. The latter aspect is of importance, since
both i.c.v. injection of a 5-HT6-receptor directed A.O.
(Bentley et al. 1997) and systemic injection of a selective
5-HT6 receptor antagonist Ro 04-6790 (Bentley et al.
1999b; Woolley et al. 2000) cause hypophagia that would
confound interpretation of food motivated operant tasks
(Meneses et al. 2001). Thus, using an ITI of 1 min, the
novel object discrimination task used in the current study
assesses short-term recognition memory. Importantly, the
pharmacological validity of the rodent novel object
discrimination task to predict novel compounds with
potential clinical advantage has also been demonstrated
since Aricept (donepezil, E2020), currently used for the
symptomatic relief in Alzheimer’s disease, was found to
reverse an age-related deficit in this task (Ni et al. 2001).
However, to date the neural substrates of novel object
discrimination have not been conclusively defined. Several
groups have suggested participation of the perirhinal and
entorhinal cortices (Wiig and Bilkey 1995; Ennaceur et al.
1996, 1997; Aggleton et al. 1997; Ennaceur 1998), cortical
association areas (Steckler et al. 1998) and the globus
pallidus (Ennaceur 1998). In contrast, the role of the
hippocampus is more controversial (Steckler et al. 1998).
Thus, although electrolytic lesions of the septal-hippocam-
pal pathway have no effect on novel object discrimination
(Ennaceur 1998) conflicting results have been obtained
following lesions of the fimbria-fornix pathway (Ennaceur
and Aggleton 1994; Ennaceur et al. 1996, 1997; Mostafa
and Ennaceur 2001) and radiofrequency lesions of the
hippocampus (Clark et al. 2000; Aingie et al. 2002;
Mumby et al. 2002). Yet, profound hippocampal lesion by
ischaemia does induce impairment (Woods and Philips
1991), which becomes apparent with intertrial intervals
between 1 and 10 min (Clark et al. 2000; Mumby et al.
2002), consistent with it being involved in recognition
memory but not the appreciation of novelty per se. One
possible explanation for this apparent disparity is that novel
object discrimination impairment is only induced following
severe hippocampal lesions and intertrial intervals of
greater than 1 min, as used herein.
The current study examines the effect of Ro 04-6790
on novel object discrimination, both when given alone
and following the impairments induced by a muscarinic or
a dopamine D2 receptor antagonist.
Materials and methods
Animals and drug treatment
Adult male Lister hooded rats (Biomedical Services Unit, Univer-
sity of Nottingham) weighing 200–400 g were housed in groups of
four on a 12 h light/dark cycle (lights on 7.00 a.m.) and given food
and water ad libitum. Room temperature (21€1C) and humidity
(55–65%) were kept constant. Rats were randomly assigned to one
of 14 treatment groups (n=10–12 per group). Pretreatment
comprised scopolamine hydrobromide (0.1, 0.5 or 1 mg/kg IP),
N-methylscopolamine (0.25 or 0.5 mg/kg IP), raclopride l-tartrate
(0.1, 0.3 or 0.5 mg/kg IP), or physiological saline as the vehicle in
all cases (0.154 M, 1 ml/kg IP). Twenty minutes later, rats were
treated with either saline (IP), or the selective 5-HT6 receptor
antagonist Ro 04-6790 (10 or 30 mg/kg IP).
Each individual group of 10–12 rats was tested twice 7 days
apart with a different pair of pretreatment/treatment conditions. On
the second test, each rat was given the opposite pretreatment so that
all rats received both treatments, such as saline and a chosen drug
dose and thus served as their own control. Each rat was only re-
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tested once in order to avoid habituation to the two objects used for
all studies. Further repeated testing with alternative objects was not
performed, to avoid potential habituation to the task. All experi-
ments were performed in accordance with the UK Animals
(Scientific Procedures) Act 1986, by an observer who was unaware
of the treatment given.
Behavioural testing
The novel object discrimination test used in the present study was a
modification of that described by Ennaceur and Delacour (1988). The
apparatus comprised a clear Perspex box as the arena, measuring
3923.5 cm with 30 cm high walls. The objects to be discriminated
were plastic bottles (8 cm high5 cm outer diameter) covered in white
masking tape (familiar objects) or black and white striped masking
tape (novel object). Each bottle was inverted and secured with Blue
Tac through holes in the floor located 10 and 5 cm from either side
and 5 cm from the end wall in opposite corners of the arena. The
weight of each bottle was such that the rats could not displace it.
Twenty-four hours prior to testing, each rat was habituated to
the arena for 60 min in the absence of any object. A total of 12
arenas were used and each rat was tested in the arena that it was
habituated to. On test days, each group of rats received drug or
saline pretreatment 20 min prior to the second drug or saline
treatment and 20 min later testing began. Each rat was placed in the
arena for 3 min in the absence of the objects for a second brief
habituation period and then for two consecutive 3-min trial periods
(T1 and T2, respectively). All three encounters with the arena were
separated by an inter-trial interval (ITI) of 1 min, during which the
rat was returned to the home cage. In the first trial (T1), rats were
exposed to two objects of identical size, shape and pattern (objects
a1 and a2). In the second trial (T2) one of the bottles “a2” was
replaced with a bottle of identical size and shape but with
alternating horizontal black and wipe stripes (“b”, the novel object),
whilst a1 was replaced with an object identical to those used in T1
(the familiar object, “a”). During T1 and T2 the exploration of either
object was defined as the time spent (s) sniffing, licking, chewing
or touching it with the nose or within 1 cm of it with moving
vibrissae and was recorded separately for each object by stopwatch.
Sitting on the object was not regarded as exploratory activity (but
rarely occurred). Between each session, the bottles were wiped with
20% (v/v) ethanol to remove any olfactory cues. Experiments were
performed in constant light at 200 lux at floor level in the arena
between 09.00 and 13.00 hours.
Statistical analysis
Within-group comparisons of time (s) spent exploring each of the
two identical objects (a1 and a2) in trial 1 (T1) and the novel (b)
versus the familiar (a) objects in trial 2 (T2) were analysed using the
Student’s paired t-test. The effect of treatment on overall explor-
atory time in T1 and T2 and the time spent at the novel and familiar
object was compared with their appropriate controls and also
analysed using the Student’s paired t-test.
Materials
Scopolamine hydrobromide and N-methylscopolamine, were pur-
chased from Sigma Chemicals (Poole, Dorset, UK), raclopride l-
tartrate from RBI chemicals (Poole, Dorset, UK), and Ro 04-6790
was a gift from F. Hoffmann La-Roche (Basel, Switzerland).
Results
Pretreatment with scopolamine hydrobromide
Following treatment with saline all three groups of rats
spent an equal time exploring the two identical objects (a1
and a2) in the first trial (T1, Table 1), but a significantly
Table 1 Effect of increasing
concentrations of the non-se-
lective muscarinic antagonist,
scopolamine hydrobromide, the
quaternary amonium derivative,
N-methylscopolamine, the do-
pamine D2 receptor antagonist,
raclopride and the selective 5-
HT6 receptor antagonist, Ro 04-
6790, both given alone and as a
combined treatment with sco-
polamine or raclopride, on the
time spent (s, mean€SEM) ex-
ploring the two identical objects
(a1 and a2) in trial 1. For each
separate drug study, the saline
data were pooled, as there was
no significant difference be-
tween the groups
Treatment group Treatment (mg/kg IP) Number
of rats
Total
exploration
of a1 (s)
Total
exploration
of a2 (s)
Scopolamine Saline 35 25€2 27€2
0.1 scopolamine 12 26€3 29€2
0.5 scopolamine 12 18€3 19€2
1.0 scopolamine 11 19€3 20€8
N-Methylscopolamine Saline 24 21€2 22€1
0.25 scopolamine 12 14€3 19€3
0.5 scopolamine 12 16€2 16€3
Raclopride Saline 36 24€1 21€3
0.1 raclopride 12 24€8 23€3
0.3 raclopride 12 16€2 17€1
0.5 raclopride 12 18€3 16€3
Ro 04-6790 Saline 21 31€2 30€1
10 Ro 04-6790 12 29€2 29€2
30 Ro 04-6790 9 21€5 21€5
0.5 scopolamine+
10 Ro 04-6790
Saline 12 17€2 21€3
0.5 scopolamine 24 20€2 21€1
0.5 scopolamine+10 Ro 04-6790 12 23€2 24€2
1.0 scopolamine+
10 Ro 04-6790
Saline 12 25€3 27€4
1.0 scopolamine 24 26€2 27€2
1.0 scopolamine+10 Ro 04-6790 12 27€2 27€2
0.1 raclopride+
10 Ro 04-6790
Saline 12 22€3 19€2
0.1 raclopride 24 22€2 20€2
0.1 raclopride+10 Ro 04-6790 12 14€2 13€1
0.3 raclopride+
10 Ro 04-6790
Saline 12 21€1 20€1
0.3 raclopride 24 17€1 18€1
0.3 raclopride+10 Ro 0-46790 12 20€1 19€1
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greater time exploring the novel (b) versus the familiar
object (a) in the second trial (T2, P<0.01, in each case,
Fig. 1A), showing that they were able to discriminate the
novel object during the choice trial. Following treatment
with scopolamine (0.1–1 mg/kg IP), all rats also spent an
equal time exploring the two identical objects (a1 and a2)
in T1 (Table 1). However, scopolamine (0.1, 0.5, and
1 mg/kg) caused a dose-dependent impairment of novel
object discrimination in T2, such that rats spent equivalent
times exploring the novel and the familiar objects
(Fig. 1A). This effect was most pronounced with the
two higher doses of scopolamine, since the difference in
time spent exploring the novel versus the familiar object
following pretreatment with the lower dose of (0.1 mg/kg)
scopolamine just missed significance (P=0.07). Notably,
scopolamine (0.5 and 1.0 mg mg/kg) tended to reduce the
overall exploratory activity in T2, although when com-
pared with saline treatment in the same rats, this did not
reach significance. However, further analysis shows that
scopolamine (0.5 and 1.0 mg/kg) selectively reduced the
time spent at the novel (P=0.06 for 0.5 mg/kg and P<0.05
for 1.0 mg/kg scopolamine) and not the familiar object
when compared with saline pretreatment in the same rats
(Fig. 1A). Thus 0.5 and 1.0 mg/kg were the doses of
scopolamine chosen to examine the effect of Ro 04-6790
on a scopolamine-induced deficit in novel object dis-
crimination.
Pretreatment with N-methylscopolamine
Following treatment with saline rats spent an equal time
exploring the two identical objects during T1 and
significantly longer exploring the novel versus the
familiar object during the choice trial (P<0.001,
Fig. 1B). Similarly, following treatment with N-
methylscopolamine (both 0.25 and 0.5 mg/kg), all rats
spent an equal time exploring the two identical objects
during T1 (Table 1). In contrast to scopolamine (above),
treatment with N-methylscopolamine (0.25 or 0.5 mg/kg),
which does not penetrate into the CNS, had no effect on
the ability of the rats to discriminate the novel object in
T2. Thus all rats given N-methylscopolamine, irrespective
of dose, spent a significantly longer time exploring the
novel versus the familiar object (P<0.01 for 0.25 and
P<0.001 for 0.5 mg/kg N-methylscopolamine, Fig. 1B)
Notably, N-methylscopolamine also had no effect on total
object exploration time in either trial (Table 2).
Fig. 1 Effect of increasing concentrations (as indicated, mg/kg, IP)
of the non-selective muscarinic antagonist, scopolamine hydrobro-
mide (A), the quaternary ammonium derivative, N-methylscopo-
lamine (B), the dopamine D2 receptor antagonist, raclopride (C)
and the selective 5-HT6 receptor antagonist, Ro 04-6790 (D), on the
time spent (s, mean€SEM) exploring the novel versus the familiar
object during trial 2. Within each separate drug study, each group
of rats received a single drug dose and saline separated by an
interval of 1 week and the saline data were pooled for clarity of
presentation as there was no significant difference between the
three groups. *P<0.05, **P<0.01, ***P<0.001, aP=0.07 compared
with time spent at the novel object in the same treatment group.
fP<0.05, fffP<0.001, bP=0.06 compared with time spent exploring
the novel object following saline treatment in the same group of
rats. +P<0.05, ++P<0.01 compared with time spent at the familiar
object following saline treatment in the same group of rats
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Pretreatment with raclopride
As seen previously, following treatment with saline, rats
spent an equal time exploring the two identical objects in
the first trial (T1, Table 1) but a significantly greater time
(P<0.001) exploring the novel versus the familiar object
in the second trial (Fig. 1C). In contrast, treatment with
raclopride, irrespective of dose, impaired novel object
discrimination in T2 (Fig. 1C) without altering the pattern
of exploration in T1 (Table 1). Notably, pretreatment with
raclopride (0.3 mg/kg and 0.5 mg/kg) also reduced the
total exploratory activity in T1 when compared with that
of saline pretreatment (P<0.05 for both groups, Table 2).
This effect was also seen in T2 (P<0.01 for 0.3 mg/kg and
P<0.001 for 0.5 mg/kg, Table 2), and further analysis
showed that raclopride reduced both the time spent
exploring the novel (P<0.001 in both cases) and the
familiar object (P<0.05 for 0.3 mg/kg and P<0.01 for
0.5 mg/kg, Fig. 1C) in T2, suggesting that these doses
caused a non-selective reduction in exploration rather
than a selective attenuation of working memory. Thus the
lower doses (0.1 and 0.3 mg/kg) of raclopride were
chosen to examine the effect of Ro 04-6790 on a
raclopride-induced deficit in novel object discrimination.
Treatment with Ro 04-6790
Following treatment with saline, both groups of rats spent
an equivalent time exploring the two familiar objects during
T1 (Table 1) but significantly longer exploring the novel
versus the familiar object during T2 (P<0.01, Fig. 1D).
Treatment with Ro 04-6790 had no effect on novel object
discrimination, such that even following the highest dose
(30 mg/kg) of this 5-HT6 antagonist, rats spent an equal
time exploring the two identical objects in T1 (Table 1) and
significantly longer exploring the novel versus the familiar
object in T2 (P<0.01 for 10 mg/kg Ro 04-6790 and P<0.05
for 30 mg/kg Ro 04-6790, Fig. 1D). Thus, Ro 04-6790 had
no effect on the ability of the rats to discriminate the novel
object in T2. In contrast to the effect of the lowest dose of
Ro 04-6790, treatment with 30 mg/kg tended to reduce total
object exploration time during T2 (Table 2), but this did not
reach significance.
Ro 04-6790 reverses a scopolamine- but not a raclopride-
induced deficit in novel object discrimination
As expected from the dose-response study, pretreatment
with both 0.5 and 1 mg/kg scopolamine impaired the
ability of the rats to discriminate the novel from the
familiar object in T2 (Fig. 2A, B), without altering the
pattern of exploration in T1 (Table 1), such that in both
cases rats spent an equal time exploring the novel and
familiar objects in the choice trial. However, in both
cases, treatment with Ro 04-6790 (10 mg/kg IP) com-
pletely reversed the scopolamine-induced deficit in novel
object discrimination (Fig. 2A, B) such that rats receiving
combined treatment of scopolamine (0.5 or 1.0 mg/kg)
and Ro 04-6790 spent a significantly longer time
exploring the novel versus the familiar object in T2
(P<0.01 for 0.5 mg/kg scopolamine + Ro 04-6790 and
P<0.001 for 1.0 mg/kg scopolamine + Ro 04-6790).
Notably, when given in combination with scopolamine
(0.5 mg/kg) in T2, Ro 04-6790 (10 mg/kg) increased the
total exploratory activity compared with that in the same
rats receiving scopolamine alone (P<0.05, Table 3).
Although it failed to reach significance, Ro 04-6790
produced a similar increase in the response in rats
receiving the higher dose of scopolamine (1.0 mg/kg,
Table 3). Further analysis showed that in both cases, this
effect was accounted for by a significant increase in time
spent exploring the novel object during T2 (P<0.05 in
both cases, Fig. 2A and 2B) following combined treat-
ment with scopolamine and Ro 04-6790, consistent with
the rats selectively redirecting their exploration towards
the novel object in the choice trial.
As expected from the dose-response curve (Fig. 1C),
pretreatment with raclopride (0.3 mg/kg IP) abolished
novel object discrimination in T2 (Fig. 3B) without
altering the pattern of object exploration in T1 (Table 1).
Table 2 Effect of scopolamine,
N-methylscopolamine, raclo-
pride and the 5-HT6 antagonist,
Ro 04-6790 at the doses indi-
cated (mg/kg IP) on total object
exploration time (s, mean€-
SEM) in trial 1 (T1) and trial 2
(T2) (i.e. the total time spent at
the two familiar objects during
T1 and the novel and familiar
object during T2). For each
separate drug study the saline
data were pooled, as there was
no significant difference be-
tween the groups
Dose-response curve Treatment
(mg/kg IP)
Number
of rats
Total object
exploration
(s) in T1
Total object
exploration
(s) in T2
Scopolamine Saline 35 52€3 41€3
0.1 scopolamine 12 54€4 46€4
0.5 scopolamine 12 36€4 24€5
1.0 scopolamine 11 40€5 28€7
N-Methylscopolamine Saline 24 43€3 29€2
0.25 scopolamine 12 33€5 37€6
0.5 scopolamine 12 33€5 23€4
Raclopride Saline 36 46 €2 36€2
0.1 raclopride 12 46€5 39€5
0.3 raclopride 12 33€3* 11€3**
0.5 raclopride 12 34€6* 15€5***
Ro 04-6790 Saline 21 62€3 54€4
10 Ro 04-6790 12 58€4 49€9
30 Ro 04-6790 9 50€8 39€6
*P<0.05, **P<0.01 and ***P<0.001 compared with saline pretreatment in the same rats
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Fig. 3 Effect of combined treatment with Ro 04-6790 (10 mg/kg
IP) and 0.1 mg/kg IP raclopride (A) or 0.3 mg/kg IP raclopride (B)
on the time spent (s, mean€SEM) exploring the novel versus the
familiar object during trial 2. Within each of the studies each group
of rats received either raclopride and or raclopride and Ro 04-6790
separated by an interval of 1 week. For clarity of presentation, the
data from the two groups were pooled for each drug. *P<0.05,
***P<0.001 compared with time spent at the novel object in the
same treatment group
Fig. 2 Effect of combined treatment with Ro 04-6790 (10 mg/kg
IP) and 0.5 mg/kg IP scopolamine (A) or 1 mg/kg IP scopolamine
(B) on the time spent (s, mean€SEM) exploring the novel versus
the familiar object during trial 2. Within each of the studies the two
groups of rats received either scopolamine and saline or scopol-
amine and Ro 04-6790 separated an interval of 1 week. For clarity
of presentation the data from the two groups were pooled for each
drug. *P<0.05, **P<0.01, ***P<0.001 compared with time spent at
the novel object in the same treatment group. fP<0.05 compared
with time spent exploring the novel object following treatment with
scopolamine alone in the same rats
Table 3 Effect of scopolamine (0.5 and 1.0 mg/kg IP) or raclopride
(0.1 or 0.3 mg/kg IP) either given alone or as a combined treatment
with Ro 04-6790 (10 mg/kg IP) on the total object exploration time
[total time spent at both objects (s, mean€SEM)] in trial 1 (T1) and
trial 2 (T2)
Treatment group Treatment (mg/kg IP) Number
of rats
Total object
exploration
(s) in T1
Total object
exploration
(s) in T2
0.5 scopolamine+10 Ro 04-6790 Saline 12 38€4 28€4
0.5 scopolamine 24 41€3 25€3
0.5 scopolamine+10 Ro 04-6790 12 47€3 60€9*
1.0 scopolamine+10 Ro 04-6790 Saline 12 51€7 47€7
1.0 scopolamine 24 50€3 47€6
1.0 scopolamine+10 Ro 04-6790 12 54€4 71€9
0.1 raclopride+10 Ro 04-6790 Saline 12 47€5 33€3
0.1 raclopride 24 42€3 31€3
0.1 raclopride+10 Ro 04-6790 12 26€2 15€3
0.3 raclopride+10 Ro 04-6790 Saline 12 41€2 34€3
0.3 raclopride 24 36€2 18€3
0.3 raclopride+10 Ro 04-6790 12 39€2 23€6
*P<0.05, compared with scopolamine treatment alone in the same rats
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Similarly, rats receiving combined treatment with raclo-
pride (0.3 mg/kg) and Ro 04-6790 (10 mg/kg) were also
unable to discriminate the novel from the familiar object
and spent an equal time at the two objects in T2 (Fig. 3B).
Conversely pretreatment with the lower dose (0.1 mg/kg)
of raclopride did not impair novel object discrimination
but combined treatment of 0.1 raclopride and Ro 04-6790
further attenuated, and led to a significant impairment of,
novel object discrimination (Fig. 3A). Thus, in contrast to
the results seen with scopolamine, Ro 04-6790 did not
reverse the raclopride-induced deficit in novel object
discrimination.
Discussion
The aim of the present study was to investigate the effect
of the selective 5-HT6 receptor antagonist, Ro 04-6790,
both when given alone and following a pharmacologically
induced deficit in a rodent model of short term recogni-
tion memory, the novel object discrimination task. Acute
systemic injection of Ro 04-6790 had no effect on novel
object discrimination when given alone but it totally
reversed the deficit induced following blockade of
muscarinic but not dopamine D2 receptors.
The centrally active, non-selective muscarinic receptor
antagonist, scopolamine, has been widely used to demon-
strate the cholinergic involvement in memory and cog-
nition in rodents. Peripheral administration of
scopolamine produces deficits in a variety of spatial tests
such as the delayed matching to position (Dunnett 1985)
and the Morris water maze (Harder et al. 1996). In
addition, deficits in non-spatial working memory tests
such as spontaneous alternation (Pontecorvo et al. 1991),
novel object discrimination (Ennaceur and Meliani 1992)
and continuous non-matching tasks (Wan et al. 1997)
occur following muscarinic antagonist administration.
Consistent with these findings, pretreatment with scopol-
amine at doses equivalent to those used in the aforemen-
tioned studies (Dunnett 1985; Ennaceur and Meliani
1992) also produced impaired novel object discrimination
in the current study. In contrast, acute, systemic injection
of the quaternary ammonium derivative N-methylscopo-
lamine, that does not penetrate the blood-brain barrier and
therefore has no CNS activity, had no effect on novel
object discrimination, consistent with previous reports
(Dunnett 1985; Ennaceur and Meliani 1992). Taken
together, this suggests that the deficit in novel object
discrimination seen with scopolamine is mediated via
central muscarinic receptor blockade and not due to a
parasympatholytic effect on visual acuity.
In accordance with previous studies demonstrating
attenuation of working memory in both spatial (Wilkerson
and Levin 1999; Umegaki et al. 2001) and non-spatial
tasks (Didriksen 1995), the selective dopamine D2
receptor antagonist raclopride also caused a dose-depen-
dent impairment of novel object discrimination. This is
consistent with the proposed role of dopamine D2
receptors in the regulation of memory (Noyce et al.
1993). However, the deficit in novel object discrimination
seen following treatment with the highest dose (0.3 mg/
kg) of raclopride was also accompanied by a reduction in
total object exploration, in both trials 1 and 2. Thus, in the
current study it seems that the deficit in novel object
discrimination seen with raclopride was a consequence of
the characteristic hypolocomotor effect of dopamine D2
receptor antagonists (Jackson and Westlind-Danielsson
1994; Feldman et al. 1997), rather than a selective
attenuation of recognition memory.
The selective 5-HT6 receptor antagonist Ro 04-6790
has been shown to have over 100-fold selectivity for the
5-HT6 receptor compared with 24 other G-protein coupled
receptors, including all muscarinic, dopamine and eight
other 5-HT receptors (Sleight et al. 1998). When given
alone, Ro 04-6790, had no effect on the ability of the rats
to perform discrimination of a novel object. However, it
completely reversed the deficit in novel object discrim-
ination produced by scopolamine, suggesting that block-
ade of 5-HT6 receptors increases cholinergic function
sufficiently to overcome central muscarinic receptor
blockade, probably by increasing acetylcholine release
(Sleight et al. 1999; Shirizai-Southall et al. 2002).
Conversely, Ro 04-6790 did not reverse the dopamine
D2 receptor antagonist-induced deficit in the same task,
consistent with previous data indicating that the 5-HT6
receptor does not modulate central dopaminergic neuro-
transmission (Bourson et al. 1995, 1998; Bentley et al.
1999a; Dawson et al. 2000, 2001). Since D2 dopamine
receptor blockade following treatment with raclopride in
the current study produces a non-selective reduction in
exploratory behaviour, the fact that Ro 04-6790 did not
reverse this non-specific behavioural disturbance, but did
reverse a selective reduction in novel object discrimina-
tion following scopolamine, further supports a role for the
5-HT6 receptor in memory processes.
Consistent with the data in the current study, several
lines of evidence suggest that 5-HT6 receptors regulate
central cholinergic neurotransmission. For instance, both
5-HT6-directed A.O. (Bourson et al. 1995) and Ro 04-
6790 (Sleight et al. 1998) produced yawning, stretching
and chewing that was antagonised by the muscarinic
receptor antagonists atropine and scopolamine (Bourson
et al. 1995; Bentley et al. 1999a). Routledge et al. (1999)
also demonstrated that another 5-HT6 antagonist, SB-
271046 (Bromidge et al. 1999), enhanced physostigmine-
induced yawning. Since the behavioural responses were
seen after treatment with a 5-HT6 receptor-directed A.O.
or a selective antagonist, it has been proposed that this
receptor receives tonic serotonergic input or possesses
constitutive activity (Bourson et al. 1995). Furthermore,
after unilateral 6-OHDA lesions of the medial forebrain
bundle, both atropine- and scopolamine-induced ipsilat-
eral rotations, but not dopamine-induced contralateral
rotations, were inhibited by Ro 04-6790 (Bourson et al.
1998). In agreement with a 5-HT6 receptor-cholinergic
interaction in the regulation of cognition, Meneses (2001)
demonstrated that Ro 04-6790 (5 mg/kg IP) reversed a
scopolamine-induced deficit in learning consolidation in
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an autoshaping paradigm. Furthermore, two preliminary
intracerebral microdialysis reports suggest that Ro 04-
6790 and the structural analogue Ro 65-7199, increase
cortical and hippocampal extracellular acetylcholine lev-
els (Sleight et al. 1999; Shirazi-Southall et al. 2002,
respectively) and reverse scopolamine-induced deficits in
the Morris water maze and passive avoidance tests
(Sleight et al. 1999; Bs et al. 2001).
Whilst the present study demonstrates a 5-HT6 recep-
tor-cholinergic interaction, the way in which 5-HT6
receptor blockade increases acetylcholine release is
currently unknown. By using an N-terminal directed
specific antibody, we previously characterised the distri-
bution of 5-HT6-like immunoreactivity (5-HT6-LI) in the
rat brain (Woolley et al. 2000). The overall pattern
matched that reported using a C-terminal directed anti-
body (Grard et al. 1997) and the selective radioligand
[125I] 4-iodo-N-[4-methoxy-3-(4-methylpiperazin-1-
yl)phenyl]benzenesulfonamide (SB-258585, Roberts et
al. 2002), demonstrating abundant 5-HT6 receptor protein
in several of the neural areas implicated in the novel
object discrimination task, including the cortex and
hippocampus (Steckler et al. 1998; Clark et al. 2000;
Mumby et al. 2002). Furthermore, by using dual labelled
immunohistochemistry, very low levels of co-existence
were found between the 5-HT6 receptor and choline
acetyltransferase (ChAT)-LI (Woolley et al. 2000) limited
to few discrete brain regions, including the medial septal
nuclei (17% of 5-HT6 positive neurones) caudate nucleus
(19%), nucleus accumbens (16%) and some areas of the
cortex (5–8% in the cingulate, frontal and parietal
corticies). Taken together, these data suggest that whilst
a direct 5-HT6 receptor activation of cholinergic neurones
may occur in these areas, in some regions the predom-
inant form of interaction may not be direct. Conversely,
abundant and extensive co-existence was seen between 5-
HT6-LI and GAD67-LI, a marker of GABAergic neurones
in 29 out of the 42 brain regions examined (Woolley et al.
2000). Such co-existence is in accordance with previous
evidence of 5-HT6 receptor-GABA co-existence in the
striatum (Ward and Dorsa 1996; Grard et al. 1997), and
suggests that this may be an important method of
interaction. Therefore, the 5-HT6 receptor-regulation of
cholinergic neurotransmission may occur via inhibition of
GABA and thence disinhibition of acetylcholine release,
as previously described for the 5-HT3 receptor (Ramirez
et al. 1996; Diez-Ariza et al. 1998).
Interestingly, Dawson et al. (2001) recently demon-
strated that the 5-HT6 receptor antagonist, SB-271046,
caused a tetrodotoxin-sensitive increase in extracellular
glutamate release by microdialysis in the frontal cortex
and dorsal hippocampus (but not in the striatum or
nucleus accumbens) of conscious adult rats. Furthermore,
Meneses (2001) demonstrated that Ro 04-6790 partially
reversed an impairment in learning consolidation pro-
duced by the NMDA receptor antagonist, dizocilpine,
consistent with the idea that 5-HT6 receptor-modulation
of glutamate may also contribute to the effect of 5-HT6
receptor antagonists on memory processing. Interestingly,
serotonergic median raph afferents preferentially inner-
vate inhibitory GABAergic interneurones in the hippo-
campus and dentate gyrus (Freund et al. 1990; Freund
1992) and thus is consistent with the proposal that 5-HT6
receptor regulation of glutamate may occur indirectly via
inhibition of GABA in this area. Indeed, Dawson et al.
(2001) showed that cholinergic-regulation of glutamate
release in this area is unlikely, since atropine had no
effect on SB-271046-induced extracellular glutamate
release. However, the possibility that cholinergic neuro-
transmission increases as a result of elevated glutamater-
gic neurotransmission has not been investigated in this
region and cannot be ruled out, since cholinergic
interneurones are present, albeit at low levels (Vizi and
Kiss 1998), and such an interaction has been demonstra-
ted in the rat striatum (Consolo et al. 1996).
In summary, the current study demonstrates that acute
systemic administration of Ro 04-6790 selectively re-
verses a cholinergic-induced deficit in a rodent model of
short term recognition memory. Whilst the underlying
mechanism of action remains to be elucidated the current
findings add further support for a role of the 5-HT6
receptor in the regulation of memory processes.
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